MovDisordV3, Main, Exploration, bibRecord, 000064

Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.

Identifieur interne : 000064 ( Main/Exploration ); précédent : 000063; suivant : 000065

Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.

Auteurs : Xuemei Huang [États-Unis] ; Alvaro Alonso ; Xuguang Guo ; David M. Umbach ; Maya L. Lichtenstein ; Christie M. Ballantyne ; Richard B. Mailman ; Thomas H. Mosley ; Honglei Chen

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.

RBID : pubmed:25639598

Abstract

Previous findings on the association of statins, plasma lipids, and Parkinson's disease (PD) are confounded by the fact that statins also affect lipid profiles. We prospectively examined plasma lipids and statin use in relation to PD in the Atherosclerosis Risk in Communities (ARIC) Study. Statin use and plasma lipids were assessed at baseline (visit 1, 1987-89) and at three triennial visits thereafter (visits 2-4) until 1998. Potential PD cases were identified from multiple sources and validated where possible. The primary analysis was limited to incident PD cases diagnosed between 1998 and 2008. Odds ratios and 95% confidence intervals were derived from multivariate logistic regression models. Statin use was rare at baseline (0.57%) but increased to 11.2% at visit 4. During this time frame, total-cholesterol levels decreased, particularly among statin users. Fifty-six PD cases were identified after 1998. Statin use before 1998 was associated with significantly higher PD risk after 1998 (odds ratio = 2.39, 95% confidence interval 1.11-5.13) after adjusting for total cholesterol and other confounders. Conversely, higher total cholesterol was associated with lower risk for PD after adjustment for statin usage and confounders. Compared with the lowest tertile of average total cholesterol, the odds ratios for PD were 0.56 (0.30-1.04) for the second and 0.43 (0.22-0.87) for the third tertile (P(trend) = 0.02). Statin use may be associated with a higher PD risk, whereas higher total cholesterol may be associated with lower risk. These data are inconsistent with the hypothesis that statins are protective against PD.

DOI: 10.1002/mds.26152
PubMed: 25639598

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.</title>
<author><name sortKey="Huang, Xuemei" sort="Huang, Xuemei" uniqKey="Huang X" first="Xuemei" last="Huang">Xuemei Huang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alonso, Alvaro" sort="Alonso, Alvaro" uniqKey="Alonso A" first="Alvaro" last="Alonso">Alvaro Alonso</name>
</author>
<author><name sortKey="Guo, Xuguang" sort="Guo, Xuguang" uniqKey="Guo X" first="Xuguang" last="Guo">Xuguang Guo</name>
</author>
<author><name sortKey="Umbach, David M" sort="Umbach, David M" uniqKey="Umbach D" first="David M" last="Umbach">David M. Umbach</name>
</author>
<author><name sortKey="Lichtenstein, Maya L" sort="Lichtenstein, Maya L" uniqKey="Lichtenstein M" first="Maya L" last="Lichtenstein">Maya L. Lichtenstein</name>
</author>
<author><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name>
</author>
<author><name sortKey="Mailman, Richard B" sort="Mailman, Richard B" uniqKey="Mailman R" first="Richard B" last="Mailman">Richard B. Mailman</name>
</author>
<author><name sortKey="Mosley, Thomas H" sort="Mosley, Thomas H" uniqKey="Mosley T" first="Thomas H" last="Mosley">Thomas H. Mosley</name>
</author>
<author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25639598</idno>
<idno type="pmid">25639598</idno>
<idno type="doi">10.1002/mds.26152</idno>
<idno type="wicri:Area/PubMed/Corpus">000281</idno>
<idno type="wicri:Area/PubMed/Curation">000281</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000064</idno>
<idno type="wicri:Area/Ncbi/Merge">004228</idno>
<idno type="wicri:Area/Ncbi/Curation">004228</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004228</idno>
<idno type="wicri:Area/Main/Merge">000064</idno>
<idno type="wicri:Area/Main/Curation">000064</idno>
<idno type="wicri:Area/Main/Exploration">000064</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.</title>
<author><name sortKey="Huang, Xuemei" sort="Huang, Xuemei" uniqKey="Huang X" first="Xuemei" last="Huang">Xuemei Huang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alonso, Alvaro" sort="Alonso, Alvaro" uniqKey="Alonso A" first="Alvaro" last="Alonso">Alvaro Alonso</name>
</author>
<author><name sortKey="Guo, Xuguang" sort="Guo, Xuguang" uniqKey="Guo X" first="Xuguang" last="Guo">Xuguang Guo</name>
</author>
<author><name sortKey="Umbach, David M" sort="Umbach, David M" uniqKey="Umbach D" first="David M" last="Umbach">David M. Umbach</name>
</author>
<author><name sortKey="Lichtenstein, Maya L" sort="Lichtenstein, Maya L" uniqKey="Lichtenstein M" first="Maya L" last="Lichtenstein">Maya L. Lichtenstein</name>
</author>
<author><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name>
</author>
<author><name sortKey="Mailman, Richard B" sort="Mailman, Richard B" uniqKey="Mailman R" first="Richard B" last="Mailman">Richard B. Mailman</name>
</author>
<author><name sortKey="Mosley, Thomas H" sort="Mosley, Thomas H" uniqKey="Mosley T" first="Thomas H" last="Mosley">Thomas H. Mosley</name>
</author>
<author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Previous findings on the association of statins, plasma lipids, and Parkinson's disease (PD) are confounded by the fact that statins also affect lipid profiles. We prospectively examined plasma lipids and statin use in relation to PD in the Atherosclerosis Risk in Communities (ARIC) Study. Statin use and plasma lipids were assessed at baseline (visit 1, 1987-89) and at three triennial visits thereafter (visits 2-4) until 1998. Potential PD cases were identified from multiple sources and validated where possible. The primary analysis was limited to incident PD cases diagnosed between 1998 and 2008. Odds ratios and 95% confidence intervals were derived from multivariate logistic regression models. Statin use was rare at baseline (0.57%) but increased to 11.2% at visit 4. During this time frame, total-cholesterol levels decreased, particularly among statin users. Fifty-six PD cases were identified after 1998. Statin use before 1998 was associated with significantly higher PD risk after 1998 (odds ratio = 2.39, 95% confidence interval 1.11-5.13) after adjusting for total cholesterol and other confounders. Conversely, higher total cholesterol was associated with lower risk for PD after adjustment for statin usage and confounders. Compared with the lowest tertile of average total cholesterol, the odds ratios for PD were 0.56 (0.30-1.04) for the second and 0.43 (0.22-0.87) for the third tertile (P(trend) = 0.02). Statin use may be associated with a higher PD risk, whereas higher total cholesterol may be associated with lower risk. These data are inconsistent with the hypothesis that statins are protective against PD.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
</list>
<tree><noCountry><name sortKey="Alonso, Alvaro" sort="Alonso, Alvaro" uniqKey="Alonso A" first="Alvaro" last="Alonso">Alvaro Alonso</name>
<name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name>
<name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name>
<name sortKey="Guo, Xuguang" sort="Guo, Xuguang" uniqKey="Guo X" first="Xuguang" last="Guo">Xuguang Guo</name>
<name sortKey="Lichtenstein, Maya L" sort="Lichtenstein, Maya L" uniqKey="Lichtenstein M" first="Maya L" last="Lichtenstein">Maya L. Lichtenstein</name>
<name sortKey="Mailman, Richard B" sort="Mailman, Richard B" uniqKey="Mailman R" first="Richard B" last="Mailman">Richard B. Mailman</name>
<name sortKey="Mosley, Thomas H" sort="Mosley, Thomas H" uniqKey="Mosley T" first="Thomas H" last="Mosley">Thomas H. Mosley</name>
<name sortKey="Umbach, David M" sort="Umbach, David M" uniqKey="Umbach D" first="David M" last="Umbach">David M. Umbach</name>
</noCountry>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Huang, Xuemei" sort="Huang, Xuemei" uniqKey="Huang X" first="Xuemei" last="Huang">Xuemei Huang</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000064 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000064 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25639598
   |texte=   Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25639598" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.

Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.